From July 1, DiaUnion is scaling up with a goal of screening 45,000 people in Denmark and southern Sweden. The aim is to reduce the bottleneck that the identification of individuals in stage 1 and 2 represents, for the development and employment of new therapies to delay the clinical onset of type 1 diabetes.
DiaUnion 2.0 is a public-private collaboration between Lund University, Steno Diabetes Center Copenhagen, Medicon Valley Alliance, Region Hovedstaden, Region Skåne og Sanofi.
Read the article (in Swedish) in the Hållbar Hälsa & Livsstil supplement, which is distributed with the Dagens Nyheter today.
